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Abstract
Background: The majority of studies of integrative treatment for colorectal cancer (CRC) have been pub-
lished in Chinese journals. These studies indicate potential benefits, but concerns have been raised over the
quality of trials published in Chinese journals. The CONSORT statement provides a guide for study reporting
that has been endorsed by more than 400 international journals. Previous studies have used the CONSORT
checklist to assess the quality of randomized controlled trials (RCTs).
Objectives: This study focused on RCTs of integrative and traditional medicine for CRC published in Chinese
journals and assessed: (1) the overall quality of reporting with a focus on methodological aspects; (2) change
over time; and (3) the influence of study funding, level of institution conducting the trial, rank of the journal,
and the length of the article.
Design: Searches of seven databases identified RCTs. Quality was assessed using CONSORT 2010 with
adaptations to facilitate scoring. Additional codes were added for publication year, hospital rank, report length,
and status of the journal. Scores of each checklist item, total scores, and scores for eight items associated with
RCT methodology were calculated.
Results: Eighty-one studies were included in the main analyses. The RCT methodology subgroup scores were
significantly higher in studies: with public funding, conducted by authors from university hospitals, published in
higher ranked journals, and in longer articles.
Conclusions: Few Chinese journals mention CONSORT in their author guidelines. In these RCTs on CRC
better reporting of RCT methodology was associated with ranking of the journal as ‘‘core,’’ public funding of
the RCT, and first or correspondent author from a university hospital but the quality of reporting had not
significantly improved in 15 years. As the volume of scientific information produced in China grows, it is
imperative that there is growth in the quality of this information.
Keywords: CONSORT checklist, colorectal cancer, reporting quality, integrative medicine, China
Introduction
In the field of medicine and health, 1055 Chinese jour-nals published 644,950 articles in 2013. Of these, the 901
journals dealing with clinical research published 518,016
articles.1 A substantial proportion of these articles reported
the results of clinical trials, but data on the exact number are
not available. Based on current trends the number of journal
articles published in China is projected to continue to in-
crease.2 It has been estimated that 146 Chinese journals
have been indexed in MEDLINE and PubMed3,4 and about
205 Chinese journals have been indexed in MEDLINE or
1The China-Australia International Research Centre for Chinese Medicine, School of Health and Biomedical Sciences, RMIT
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EMBASE5 amounting to about 8% of the estimated 2529
journals included in the five main Chinese biomedical and
scientific databases.4 Consequently much of the medical
and healthcare research conducted in China is not available
to international medical researchers due to language barriers
and the relatively small numbers of reports that are ab-
stracted in international databases.
In addition, there is the issue of whether the conduct of
randomized controlled trials (RCTs) reported in Chinese
journals was in accord with international standards. Wu et al.
conducted telephone interviews with the authors of 2235 ar-
ticles published from 1994 to 2005 that reported results of
RCTs and found that only 6.8% adhered to established RCT
methodology. There was no difference between trials of
conventional and traditional medicine in terms of methodo-
logical quality. In their stratification analysis, all premarket
drug trials were authentic RCTs, and 51.6% of government
funded studies were considered authentic. In China, hospitals
are categorized into three grades according to their level and
size, the highest level being level 3 which are hospitals af-
filiated to medical universities and provincial hospitals, other
hospitals are classified as level 2 or below. The authors found
that hospitals affiliated to medical universities were better in
conducting RCTs than other level 3 hospitals and level 2
hospitals.6 A study of 70 Cochrane systematic reviews of
studies of Chinese traditional medicine found that most re-
views produced inconclusive outcomes due to poor method-
ology and heterogeneity of the included studies.7
Assessment of the quality of a clinical trial depends on
whether the design, conduct, and analysis are adequately re-
ported in the publication. Although there is no uniform inter-
national guideline for reporting clinical trials, the CONSORT
statement which was introduced in 1996 has been endorsed
by more than 400 international journals and several edito-
rial groups. The current version includes checklists that
provide guidance for authors to report their trials clearly and
completely.8 In China, there is a relatively low level of en-
dorsement. Li et al. reported that 6 of 195 high-impact med-
ical journals (3.08%) mentioned CONSORT in the author
guidelines9 and Song et al. reported that 7 of 1221 (0.57%)
medical journals endorsed CONSORT.10 Only 1 of 90 jour-
nals of Chinese traditional medicine (English version only)
and one specialist oncology journal endorsed CONSORT.
The CONSORT checklist8 has been used as measure of
quality of reporting in RCTs. A study of 76 RCTs of inte-
grative medicine published in two Chinese journals before
and after adoption of CONSORT found that adoption and
length of the article both improved the quality of report-
ing.11 An earlier study of the reporting of CONSORT 2001
items in studies of traditional medicine published in Chinese
journals from 1999 to 2004 found inadequate reporting with
only 7.9% providing a description of the method of gener-
ation of randomization sequence.12 A subsequent study of
6994 articles published from 2005 to 2012 that used
CONSORT 2010 items for scoring found better reporting
with 16.26% describing the randomization sequence.13
A study of adherence to CONSORT in 357 RCTs pub-
lished from 2005 to 2009 in 10 major international oncology
journals found that 29% adequately reported the method for
generation of randomization sequence, and other items were
inadequately reported. More recent publication, higher
journal impact factor (IF), and industry funding were all
predictors of higher quality of reporting.14 In comparison,
34% of 616 general medicine RCTs indexed in PubMed in
2006 adequately reported this item.15
Most Chinese language medical journals have no IF or a
low IF. For example, the Chinese medical journal, which is
the oldest medical journal in China, had an IF of 1.05 in
2015. Chinese journals are ranked by the library of Beijing
University based on nine criteria to produce lists of ‘‘core’’
journals in each field, including 37 journals in the field of
general medicine and healthcare, 24 journals specializing in
internal medicine, and 19 journals specializing in Chinese
traditional and integrative medicine.16
Integrative approaches are recommended in Chinese tra-
ditional medicine guidelines for cancer. Diagnosis is based
on biomedical criteria and treatment involves surgery, che-
motherapy, Chinese traditional therapies, and supportive or
palliative care.17 The number of RCTs of Chinese and in-
tegrative medicine for cancer has substantially increased
over the last 20 years.18 Systematic reviews of integrative
medicine indicate potential benefits for colorectal cancer
(CRC).19–22 Most of the RCTs on this topic were conducted
in China and published in Chinese journals, but the ade-
quacy of reporting can impact on confidence in the out-
comes. In the present study the authors assess the quality of
reporting based on CONSORT of RCTs of CRC treated with
traditional and integrative medicine that were published in
China. The study aims to assess: (1) the overall quality of
reporting with a focus on methodological aspects; (2)
whether there was change over time; and (3) whether study
funding, level of institution conducting the trial, rank of the
journal, and the length of the article influenced the quality of
reporting.
Materials and Methods
Searches were conducted of the databases PubMed, Co-
chrane CENTRAL, CINAHL, Science Direct, PsycINFO,
China Academic Journals (CNKI), and Chongqing VIP In-
formation (CQVIP) in the category of Chinese Science and
Technology Journals (CSTJ) from their inceptions to De-
cember 2013. Three groups of search terms were used:
(1) Study design: RCT and related terms; (2) Disorder: CRC
and related terms; (3) Intervention: herbal medicine, com-
plementary medicine, Chinese medicine, and related terms
(Supplementary Data; Supplementary Data are available on-
line at www.liebertpub.com/acm). Hand searches were con-
ducted of article reference lists to identify additional studies.
Included studies were designated RCT by the author(s),
enrolled participants who were all diagnosed with CRC
based on pathologic tests, and used traditional herbal med-
icine (with or without concurrent chemotherapy) in the test
group. Control groups could be chemotherapy, no treatment,
or placebo.
The quality of reporting in each study was assessed using
the CONSORT 2010 checklist.8 CONSORT 2010 contains
25 items but a number of these include subitems so there are
37 items in total. Items 1 to 22 were included in CONSORT
2001,23 and items 23 to 25 (other information) were added
in CONSORT 2010.8 Following a trial run using the un-
modified version, the authors found that adding two sub-
items facilitated assessment and scoring as follows: item 6a
was split into 6a(1) Primary and secondary outcomes and
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item 6a(2) Endpoints (time of data measured); and item 13a
Flow of participants was divided into item 13a(1) Flow di-
agram as figure, and item 13a(2) Flow of participants
(verbal) (Table 1). These same modifications appear in the
assessment of RCTs of medical oncology by Peron et al.14
A subgroup of eight items directly related to RCT
methodology based on Jadad’s scale24 and Cochrane risk of
bias25 was identified as follows: item 8a sequence genera-
tion method; item 8b type of randomization; item 9 allo-
cation concealment; item 10 implementation of random
allocation sequence; item 11a blinding of participants (and
others) to group assignment; item 11b description of the
similarity of interventions (if relevant); item 13b for each
group, losses and exclusions after randomization, with rea-
sons; and item 16 for each group, number of participants
(denominator) included in each analysis and whether intent-
to-treat analysis was used.8
In addition, data were entered for publication year; rank of
the hospital in China to which the first or corresponding author
was affiliated (1) university hospital, (2) other type of hospital
(provincial hospital, municipal, or county-level hospital);
length of the report based on A4 size pages rounded to the
nearest half page; and whether or not the report was published
in a leading (core) journal based on the ranking by Beijing
University library16; reporting of syndrome according to
Chinese medicine theory26; and whether or not the journal
endorsed CONSORT in the author guidelines.
Data were independently extracted into a predesigned excel
table byM.C. and J.C. The data were cross-checked by the two
data extractors. Differences were resolved through discussion.
Disagreements were mediated by BHM. Each CONSORT
checklist item was given a ‘‘yes,’’ ‘‘no,’’ or ‘‘not applicable’’
response depending on whether the item was included in the
study report. ‘‘Yes’’ was scored 1, ‘‘no’’ and ‘‘not applicable’’
were scored 0.
Data analysis
For each study the number of items reported was calcu-
lated (items 1–25, maximum score= 39), and average scores
were obtained for each publication year to investigate any trend
over time. Comparisons with reviews of Chinese journals13
and international oncology journals14 were planned.
Studies were equally divided into two groups according
to: publication year; length of the article (in pages); ‘‘core’’
journal (or not), ranking of the author’s hospital, and public
funding of the study (or not). Between-group analyses were
based on: (1) items 1–22 (maximum score of 36) since these
are the items concerned with the quality of the study report
that were included in both CONSORT 200123 and 20108 and
(2) the subgroup of eight items directly related to RCT
methodology.
Means and standard deviations (SDs) were calculated in
Excel. RevMan5.3 was used to evaluate differences between
groups. Risk ratio (RR) was used for dichotomous data and
mean difference (MD) for continuous data with 95% con-
fidence interval (95% CI) in a fixed effect model. Our hy-
pothesis was that recency of publication, length of article,
‘‘core’’ journal, ranking of the author’s hospital, and pub-
lic funding would affect reporting quality. Significant dif-
ferences were indicated by RR more than 1 or MD not less
than 0 with p-value not more than 0.05. I2 measured the
proportion of heterogeneity. If I2 was more than 50% this
indicated substantial heterogeneity.
Results
Following screening, 88 full-text studies were evaluated.
Four studies written in English published in international
journals were excluded leaving 84 studies that were pub-
lished in China. One of these studies was written in English
in a Chinese journal, and two studies were Chinese theses
published in CNKI. These three studies were excluded from
the main analysis which focused on articles in medical
journals written in Chinese (Fig. 1 flow chart). The 81 ar-
ticles were published from 1998 to 2013 in 53 different
Chinese journals. None of the earlier studies met the in-
clusion criteria. All were written in Chinese and ranged in
length from one to four pages (mean 2.44, SD –0.75). Short
articles were defined as one to two pages (n = 46), and
longer articles were three or more pages (n = 35). For pub-
lication year, the most equal division was 1998 to 2008 (43
articles) and 2009 to 2013 (38 articles). Eighteen studies
were funded by national, provincial, or local governments
(22.2%). The first or corresponding author of the study was
from a university or affiliated hospital in 42 studies (51.9%).
Twenty-one studies (25.9%) were published in core medical
journals according to the ranking by the library of Beijing
University.16 No endorsement of CONSORT in the author
guidelines was found in any of the 53 journals.
In the 81 studies, the total mean score of the checklist
items was 10.44 (SD –2.40) out of a maximum of 39. Two
items were reported by all studies (6a, 22), and 12 items
were not reported at all (items 3b, 6b, 7a, 7b, 9, 10, 12b,
13a(1), 14b, 17a, 17b, 23, 24) (Table 1). Reporting rates
were above 70% for 10 items (1b, 2a, 4a, 4b, 5, 6a(1), 6a(2),
12a, 14a, 22).
In the subgroup of eight items on RCT methodology, item
9 allocation concealment and item 10 implementation of
randomization were not reported in any study. Item 8a se-
quence generation was reported by 29.6% studies, item 13b
losses and exclusions by 12.35%, item 16 intent-to-treat
analysis by 4.94%, and item 11a blinding by 2.47%; so these
four items were the main contributors to the analyses.
Eighteen studies mentioned a form of public funding, none
mentioned commercial funding, and no studies mentioned
published protocols or trial registration. Chinese medicine
syndromes were reported in 37.03% of studies (Table 1).
In the single study published in English27 the total score
was 29 and the two theses written in Chinese had an average
score of 14.28,29 None of these mentioned the three other
information items.
Change in reporting over time
There was no significant difference in total scores or in
the eight items for RCT methodology for studies published
during 1998–2008 (n = 43) and 2009–2013 (n = 38). No
items were significantly lower. Two items (2a, 12a) were
significantly improved in 2009–2013 (Table 2).
Effect of length of article
When articles of three pages or more were compared to
those with less than three pages, there was no difference in
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total scores, but the scores for the eight-item subgroup were
significantly higher in the longer articles (RR 1.72 [1.01,
2.92], I2= 0%). Longer articles were more likely to mention
RCT in the title (item 1) and state specific objectives or hy-
potheses (item 2b) (Table 2).
Effect of core versus noncore journal
There was no significant difference in total scores between
core journals and noncore journals but the eight-item sub-
group scores were significantly higher in the core journal
group (RR 1.73 [1.01, 2.98], I2= 0%). Articles in core jour-
nals were more likely to state specific objectives or hypoth-
eses (item 2b) (Table 2).
Effect of public funding
There was no statistical difference between studies with
public funding and studies without for total scores but
studies with public funding were significantly better on the
eight-item subgroup (RR 2.78 [1.64, 4.74], I2 = 13%). In
addition, there were significant improvements in items: item
1a RCT in the title, item 2a scientific background and study
rationale, item 13b losses and exclusions after randomiza-
tion, and item 16 analysis of intent to treat (Table 2).
Rank of author’s hospital
The total reporting rate was not different between articles
from authors affiliated with university hospitals and articles
from lower ranking hospitals, but the eight-item subgroup
scores were significantly higher in articles from university
hospitals (RR 1.90 [1.07, 3.38], I2= 0%), although there were
no differences for specific items (Table 2).
Discussion
In this review the quality of reporting of 81 RCTs of the
management of CRC published in Chinese journals was an-
alyzed using items from the CONSORT 2010 checklist and a
subgroup of eight items that described key aspects of RCT
methodology. Most of the included studies were brief (two to
three pages) consisting of title, abstract, text body, tables, and
references. This style of bulletin-like reporting limited the
amount of included information. Thirteen items were not
reported in any study, including sample size determination
(items 7a, 7b), allocation concealment (item 9), and im-
plementation of random-allocation sequence (item 10). In
addition, no study included a flow diagram and only 2.47%
verbally described participant flow (items 13a(1) and 13a(2)).
In Li et al.,13 these items were reported in less than 1% of
FIG. 1. Flow diagram of
the search and selection pro-
cess of RCTs of integrative
and TM for CRC published
in China. CRC, colorectal
cancer; CT, clinical trial of
TM without randomization;
DU, duplicate publication;
MT, multi-cancer CT; Other,
not a controlled trial, not a
CT of TM; RCT, randomized
controlled trial; RE, review;
TM, traditional medicine.
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studies of traditional medicine, but flow diagram was not
scored separately. Overall, the pattern of results of this study
was similar to Li et al.13 Five items (3b, 6b, 7b, 12b, 14b) had
zero reporting rates in both studies, and six items (1b, 4b, 5,
6a(1), 14a, 22) were reported by over 70% of studies in both
Li et al.13 and the present study (Table 1). Compared to
previous studies of Chinese journals, generation of random-
ization sequence was higher in this study than in Li et al.
(16.26%),13 He et al. (9%),31 and Wang et al. (7.9%).12 Re-
porting of Chinese medicine syndromes was higher than in
Wang et al. (16.7%).
A Cochrane review on the effect on CONSORT en-
dorsement on reporting quality in medical journals found
that three items (7a sample size calculation, 8a generation of
random allocation sequence, and 9 allocation concealment)
were significantly better reported in articles from CON-
SORT endorsing journals.30 In the study of oncology RCTs
in 10 well-known international journals, sample size deter-
mination was reported in 67% of articles, allocation con-
cealment in 51%, 60% provided a flow diagram, while 31%
adequately described randomization sequence generation.14
In the present analysis, generation of random allocation
sequence was reported in 29.63% of studies, while no
studies reported on the other three items. These differences
indicate gaps in the quality of reporting of oncologic RCTs
between Chinese journals and international journals.
Previous studies reported improvements in reporting of
sequence generation over time.13,31 In this study there was a
13% increase in the proportion of studies adequately de-
scribing random sequence generation between 1998–2008
(23.3%) and 2009–2013 (36.8%), but this was not statisti-
cally significantly different. It is possible that our sample of
81 studies did not have sufficient power to detect a signifi-
cant effect for this item.
The subgroup analysis results for length of article, pub-
lication in a core journal, public funding, and rank of first
author/correspondent author’s hospital found nonsignificant
differences in total scores, but there were significant dif-
ferences in the subgroup of eight items closely related to
RCT methodology. Overall, articles that were longer, pub-
lished in a core journal, publicly funded, and had a first or
correspondent author from a university hospital showed
greater adherence to these CONSORT items. This result was
consistent with previous Chinese studies.5,11,13 These as-
pects may be useful additions in assessments of the quality
of RCTs published in Chinese journals and could be used as
criteria for sensitivity analyses in meta-analyses.
Limitations of the study
The 81 RCTs reported results for CRC treated with in-
tegrative medicine, each included Chinese herbal treatment,
and all studies were published during the 15-year period
after 1997. Therefore, the results cannot be generalized to
all cancer trials published in Chinese medical journals.
Nevertheless, the overall results were similar to those found
in other surveys.12,13,31
Some of the checklist items presented scoring and inter-
pretation issues. In the title and abstract section (items 1a,
1b), only 2.47% of studies mentioned RCT in the title, but
64 studies (76.2%) stated randomization in the abstract. In
the remaining studies, the term RCT was found in the
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introduction or method section. Therefore screening of title
and abstract alone was not sufficient for the Chinese studies
to be identified as RCTs. Item 15 specified the use of a table
of baseline information which was provided in only 13
studies (16.05%), but 77 studies verbally described the
baseline information and only one study didn’t report
baseline information. Therefore reporting of baseline in-
formation was much better than the scoring system suggests.
No study reported outcome data as specified by CONSORT
2010 (items 17a, 17b), but all provided numerical data
suitable for use in meta-analysis, including mean with SD,
rate, and p-value. Consequently, data reporting was not as
poor in these Chinese studies as the ratings suggest. Ten
studies reported losses and exclusions (item 13b) and four of
these imputed losses back in the final analysis (item 16), but
there were no losses in the other studies. Since there were no
available pretrial protocols for these studies, the authors
could not confirm that the final analysis number was the
original randomization number. Therefore these studies
were judged ‘‘NA’’ and received a zero score. The oncology
studies tended to be of inpatients and of short duration so
few dropouts were plausible. Li et al.13 also found low at-
trition rates in Chinese trials. Few studies provided clear
statements of trial design (item 3a) such as specifying that
the study was prospective with parallel groups. However, 79
out of 81 included studies were two armed controlled
studies, 37 had equal numbers of participants in both arms,
while another two studies were three armed controlled trials.
Considering the brevity of the articles it is likely that the
authors considered it apparent that a parallel design was
used. Adverse event (AE) reporting was difficult to assess in
these oncology studies since most included specific cate-
gories of chemotherapy-related events as outcome measures.
To provide a comparison with Li et al., the authors only
scored reports of AEs associated with the traditional medi-
cine interventions. These showed a low level of reporting
but most intervention groups combined traditional medicine
with chemotherapy so the chemotherapy-related events were
not distinguished from those of the traditional medicines.
These examples illustrate difficulties in using the CON-
SORT 2010 checklist in assessing reporting quality. In-
complete explicit reporting of an item leads to a score of zero
although the item may have been partially reported and some
items are not applicable in certain studies. Of the eight-item
subgroup, items 8b and 10 presented scoring difficulties and
11b may be applicable to certain types of studies only.
Nevertheless, the other five items could provide a useful
subscore for RCT methodology.
Future directions
There have been a number of calls to improve the qual-
ity of reporting in Chinese journals of clinical trials of
traditional11,26,31–37 and general medicine.9,10,38–40 As
Moher et al. have noted, clinical trial reporting needs to be
clear, complete, and transparent; poorly conducted clinical
trials waste resources and could mislead decision makers.8
This issue is especially important for trials of traditional
medicine because the majority of these trials are conducted
in China and reported in Chinese journals. The following
suggestions may help to improve reporting of clinical trials
in China:
(1) Personnel education. According to Wu et al., up to
85% of trial authors in China have not correctly in-
terpreted the methodological principles of random-
ized trials.6 So all personnel who participate in a
clinical trial should be properly trained before con-
ducting a RCT.
(2) Require trial registration and a written protocol as a
precondition of publication. This can help prevent
selective reporting of outcomes, data mistreatment,
and duplicated publication.8 Registration of a clinical
trial is becoming a requirement for publication in
medical journals worldwide. A survey of the in-
structions to authors found that 44 out of 165 ‘‘high
impact factor medical journals’’ stated that all recent
clinical trials must be registered as a requirement of
submission to that journal.41
(3) Improve publishing guidelines. DerSimonian et al.42
pointed out that editors could improve the reporting
of clinical trials by providing authors with a list of
items to be strictly reported. Empirical evidence has
proven that checklists can improve the quality of
reporting of clinical trials internationally15,43 and in
China.10,11,44,45 Thus, Chinese journals should require
that CONSORT and the extensions for traditional
medicine26 be followed as a requirement for sub-
mission.
(4) Balance the need for short articles with the need for
complete reporting. Brief reporting has long been the
norm in Chinese medical articles and it is a challenge
to completely report an RCT according to the CON-
SORT checklist in two to three pages in a hard copy
journal. However, with the use of modern technology
greater detail can be included in Supplementary Data
and online resources to provide the interested reader
and researchers with the data required to assess the
quality of the study.
These reforms are all feasible and their implementation
would likely lead to greater international impact of clinical
research conducted in China.
Conclusions
Relatively few Chinese journals mention CONSORT in
their author guidelines, and the quality of reporting of RCTs
in Chinese journals remains inadequate. Features of Chinese
articles that were associated with better reporting of RCT
methodology included ranking of the journal as ‘‘core,’’
public funding of the RCT, and first or correspondent author
from a university hospital. Some studies have found im-
provements in reporting over the past decade, but this
sample of RCTs on CRC found little improvement in 15
years. As the volume of scientific information produced in
China continues to grow, it is imperative that there is
growth in the quality of this information and its interna-
tional impact.
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